[99mTc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expression

Autor: Muhummad Sohaib Nazir, Daniel Johnathan Hughes, Gitasha Chand, Kathryn Adamson, Jessica Johnson, Damion Bailey, Victoria Gibson, Hong Hoi Ting, Alexander R. Lyon, Gary J. R. Cook, PECan study group

Publikováno v: EJNMMI Research, Vol 13, Iss 1, Pp 1-8 (2023)

Abstract Background Myocardial programmed death-ligand 1 (PD-L1) expression is implicated in immune checkpoint inhibitor (ICI)-associated myocarditis. Measurement of myocardial PD-L1 expression may have potential use as a mechanistic and predictive b

Externí odkaz: https://doaj.org/article/e4af95089d944a31b4f9fa21c1721e41

SPECT/CT imaging of chemotherapy-induced tumor apoptosis using 99mTc-labeled dendrimer-entrapped gold nanoparticles

Autor: Yan Xing, Jingyi Zhu, Lingzhou Zhao, Zhijuan Xiong, Yujie Li, San Wu, Gitasha Chand, Xiangyang Shi, Jinhua Zhao

Publikováno v: Drug Delivery, Vol 25, Iss 1, Pp 1384-1393 (2018)

Non-invasive imaging of apoptosis in tumors induced by chemotherapy is of great value in the evaluation of therapeutic efficiency. In this study, we report the synthesis, characterization, and utilization of radionuclide technetium-99m (99mTc)-labele

Externí odkaz: https://doaj.org/article/fe6a508e737d4ef292def624aedf2263

99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types

Autor: Betül Altunay, Andreas Goedicke, Oliver H. Winz, Fabian Hertel, Dirk von Mallek, Levente K. Meszaros, Gitasha Chand, Hans-Jürgen Biersack, Elmar Stickeler, Katja Krauss, Felix M. Mottaghy

Publikováno v: European journal of nuclear medicine and molecular imaging 50(4), 1005-1013 (2022). doi:10.1007/s00259-022-06066-3
European Journal of Nuclear Medicine and Molecular Imaging, 50(4), 1005-1013. Springer, Cham

European journal of nuclear medicine and molecular imaging (2022). doi:10.1007/s00259-022-06066-3
Published by Springer-Verl., Heidelberg [u.a.]

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::599fbaefaab18dea0d81d464273963e7
https://doi.org/10.1007/s00259-022-06066-3

Early Phase I Study of a 99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer

Autor: Jim O’Doherty, Changchun Liu, Levente K. Meszaros, Nicholas C.L. Wong, Jinhua Zhao, Lingzhou Zhao, Yan Xing, Gitasha Chand, Hong Hoi Ting, Gary Cook

Publikováno v: Journal of Nuclear Medicine
Xing, Y, Chand, G, Liu, C, Cook, G J R, O'Doherty, J, Zhao, L, Wong, N, Meszaros, L, Ting, H H & Zhao, J 2019, ' Early Phase I Study of a 99m Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer ', Journal of Nuclear Medicine, vol. 60, no. 9, pp. 1213-1220 . https://doi.org/10.2967/jnumed.118.224170

Immunotherapy with checkpoint inhibitor programmed cell death 1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies demonstrates improvements in treatment of advanced non–small cell lung cancer. Treatment stratification depends on immunohistochemic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f0361202845b0c2fe2be1f37c0fec58
http://europepmc.org/articles/PMC6735283

Retraction Note to: Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer

Autor: Gary Cook, Gitasha Chand, D.J. Hughes, Vicky Goh

Publikováno v: EJNMMI Research, Vol 11, Iss 1, Pp 1-1 (2021)
EJNMMI Research

Checkpoint inhibition therapy using monoclonal antibodies against programmed cell death protein 1 (PD-1) or its ligand (PD-L1) is now standard management of non-small cell lung cancer (NSCLC). PD-L1 expression is a validated and approved prognostic a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ab5e8c1a665fff5e6b432a6cd5e3c62
https://doaj.org/article/c045f36703964f88927d757a65827505